BLA 761365 · Astellas
Vyloy
Zolbetuximab-Clzb · Injection · Claudin 18.2-directed Cytolytic Antibody
NovelPriority reviewOrphanCDER novel approval, Oct 18, 2024: To treat gastric or gastroesophageal junction adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Jun 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Oct 18, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
24
4 Phase 3, 9 recruiting
FAERS reports
1,525
1,304 serious, 178 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 11, 2026.
VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )]. VYLOY is a claudin 18.2-directed cytolytic antibody and is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test ( 1 ).
Mechanism: Zolbetuximab-clzb is a claudin 18.2 (CLDN18.2)-directed cytolytic antibody that depletes CLDN18.2-positive cells via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Zolbetuximab-clzb in combination with chemotherapy had increased antitumor activity in CLDN18.2-expressing mouse tumor models compared to zolbetuximab-clzb or chemotherapy alone.
Therapeutic areas: Oncology · Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 6, 2025 Supplement 3 · Efficacy OrphanLabelLetter
- Oct 18, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- VYLOY · ZOLBETUXIMAB-CLZB 100MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zolbetuximab" as an intervention, any sponsor and status, largest first.
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07431281 · 2,130 participants (planned) · Start Feb 3, 2026 · Primary completion Aug 16, 2029
Drug: Sonesitatug vedotin; Rilvegostomig and 6 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 314 sites in all
- A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.Pivotal-lookingActive, not recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT03504397 · 565 participants · Start Jun 21, 2018 · Primary completion Sep 9, 2022
Drug: zolbetuximab; placebo and 3 more · For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Bakersfield, California · 218 sites in all
- A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).Pivotal-lookingActive, not recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT03653507 · 507 participants · Start Nov 28, 2018 · Primary completion Oct 25, 2022
Drug: zolbetuximab; oxaliplatin and 2 more · For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer and 1 more
Sites: Monterey, California; Fairway, Kansas; New Orleans, Louisiana · 165 sites in all
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT06901531 · 500 participants (planned) · Start May 22, 2025 · Primary completion Sep 30, 2028
Drug: zolbetuximab; Pembrolizumab and 5 more · For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer and 1 more
Sites: Birmingham, Alabama; Bakersfield, California; Cerritos, California · 253 sites in all
- A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerPivotal-lookingActive, not recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT03816163 · 393 participants · Start Mar 15, 2019 · Primary completion Oct 31, 2026
Drug: zolbetuximab; nab-paclitaxel and 1 more · For: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Sites: Fullerton, California; Whittier, California; Meriden, Connecticut · 136 sites in all
- Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric AdenocarcinomaPivotal-lookingRecruiting
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
NCT07000253 · 290 participants (planned) · Start Apr 29, 2026 · Primary completion Nov 2031
Drug: Chemotherapy; Targeted Systemic Therapy and 1 more · For: Esophageal Cancer; Gastric (Stomach) Cancer; Gastric Adenocarcinoma and 3 more
Sites: Amsterdam, Netherlands; Utrecht, Netherlands; Oslo, Norway · 5 sites in all
- Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric CancerPivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT01630083 · 252 participants · Start Jul 19, 2012 · Primary completion Jan 31, 2019
Drug: epirubicin; oxaliplatin and 2 more · For: CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction; CLDN18.2-positive Adenocarcinoma of Esophagus; CLDN18.2-positive Gastric Adenocarcinoma
Sites: Plovdiv, Bulgaria; Sofia, Bulgaria; Varna, Bulgaria · 48 sites in all
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal AdenocarcinomasRecruiting
American Association for Cancer ResearchAcademic, hospital or other
NCT07290985 · 242 participants (planned) · Start Jul 20, 2026 · Primary completion Jun 1, 2028
Drug: Tislelizumab; Leucovorin and 4 more · For: Gastroesophageal Adenocarcinoma
Sites: Los Angeles, California; New Haven, Connecticut; Houston, Texas · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea558
- vomiting271
- decreased appetite201
- ascites138
- hypoalbuminaemia129
- malignant neoplasm progression117
- blood albumin decreased100
- diarrhoea82
- oedema peripheral67
- myelosuppression66
- neutrophil count decreased63
- malaise62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 22 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 100 |
| 2025 | 772 |
| 2026 | 607 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K, Lordick F, Bang YJ, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA, Shitara K, Ajani JA, et al. · Nat Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- SPOTlight on GLOW.
Derks S, van Laarhoven HWM · Cell Rep Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ, Lee KW, Shitara K, et al. · Clin Cancer Res 2023 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U, Türeci Ö, Manikhas G, et al. · Ann Oncol 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, et al. · Ann Oncol 2019 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.